OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced Monday that, following its Special Meeting of Shareholders held March 30, 2020, OpGen shareholders overwhelmingly voted to approve the proposed business combination with Curetis N.V. OpGen reported that 95% of the votes cast were voted to approve the business combination. The business combination is expected to close in the coming days. As previously announced, on March 10, 2020, Curetis N.V. shareholders voted to approve the transaction, making Monday’s approval by OpGen’s shareholders the last major hurdle now successfully cleared to closing the planned business combination.
Read the full article: OpGen Announces Shareholder Approval for Business Combination with Curetis //
Source: https://www.globenewswire.com/news-release/2020/03/30/2008465/0/en/OpGen-Announces-Shareholder-Approval-for-Business-Combination-with-Curetis.html